In a move poised to reshape the landscape of single-cell multiomics research, BD (Becton, Dickinson and Company) and Opentrons Labworks have joined forces to integrate advanced robotic automation into BD’s instruments. This strategic partnership aims to enhance the precision and efficiency of single-cell experiments, opening new avenues for breakthroughs in medical science. By leveraging Opentrons’ expertise in lab automation and BD’s leading role in medical technology, researchers now have the opportunity to conduct experiments on a larger scale with increased speed and reproducibility, particularly within the realms of oncology, immunology, and drug development.
Collaborative Integration
The collaboration between BD and Opentrons centers around merging the BD Rhapsody™ System with the Opentrons Flex® platform. This integration promises to enable hands-free workflows for scientists, automating complex processes associated with single-cell multiomics research. Key developments include creating an automation-compatible module for the BD Rhapsody™ System, facilitating next-generation sequencing library preparation and cell capture. Such advancements are critical in simplifying the traditionally labor-intensive processes involved in these experiments, ultimately fostering more groundbreaking discoveries in the field.
Opportunities for Early Access
Researchers eager to capitalize on this innovation will soon have a chance to participate in early access opportunities. The introduction of automated processes in single-cell multiomics experiments stands to significantly reduce time and costs, making high-level research more attainable and scalable. Labs worldwide can expect to benefit from this improved operational capability, making strides in basic and translational research. Interested professionals can gather more insights and explore early access during the American Society of Human Genetics (ASHG) Annual Meeting in Boston.
As the collaboration continues to unfold, notable implications emerge:
- The alliance combines BD’s deep single-cell multiomics expertise with Opentrons’ advanced, open-source automation systems.
- Automated single-cell workflows can greatly increase the data throughput of laboratories.
- Cost efficiency in research is likely to improve, making cutting-edge experiments more accessible globally.
A successful partnership between BD and Opentrons could potentially set a new standard in life sciences research, as the integration of robotics promises to streamline workflows and foster greater scientific innovations. By overcoming current scale and speed limitations, researchers are poised to delve deeper into the layers of cellular biology, potentially accelerating discoveries in the battle against complex diseases. The benefits of this collaboration could ripple across medical and pharmaceutical research, paving the way for novel treatments and diagnostic tools.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
